Prof. Dr. med. Peter Fasching

Professur für Translationale Frauenheilkunde und Geburtshilfe

Germline variants of homology-directed repair or mismatch repair genes in cervical cancer () Kokemüller L, Ramachandran D, Schürmann P, Geffers R, Jentschke M, Böhmer G, Strauß HG, et al. Journal article Effect of delayed isolation of peripheral blood mononuclear cells on cell viability and functionality (2025) Lehle S, Völkl S, Seitz K, Goossens C, Emons J, Rübner M, Uhrig S, et al. Journal article Lessons learned from a candidate gene study investigating aromatase inhibitor treatment outcome in breast cancer (2025) Hoppe R, Winter S, Lo WY, Michailidou K, Bolla MK, Keeman R, Wang Q, et al. Journal article Prognostic impact of the choice of chemotherapy after first-line CDK4/6 inhibitor therapy in patients with metastatic hormone receptor-positive, HER2-negative breast cancer (2025) Michel LL, Ziegler P, Kreis P, Hartkopf AD, Wallwiener M, Häberle L, John N, et al. Journal article First-Line Camizestrant for Emerging ESR1 -Mutated Advanced Breast Cancer. (2025) Bidard FC, Mayer EL, Park YH, Janni W, Ma C, Cristofanilli M, Bianchini G, et al. Journal article GWAS meta-analysis identifies five susceptibility loci for endometrial cancer (2025) Ramachandran D, Wang X, Laisk T, Zheng Y, Ingold N, Canson DM, Kho PF, et al. Journal article Ovarian cancer risk and survival according to tumor sex hormone receptor expression: An ovarian Cancer association consortium and ovarian tumor tissue analysis consortium pooled analysis (2025) Fu Z, Borho L, Taylor SE, Kelemen LE, DeFazio A, Webb PM, Köbel M, et al. Journal article Treatment of Patients with Early Breast Cancer: 19th St. Gallen International Breast Cancer Consensus Discussed against the Background of German Treatment Recommendations (2025) Untch M, Banys-Paluchowski M, Brucker SY, Denkert C, Fasching P, Haidinger R, Harbeck N, et al. Journal article, Review article Conditional progression-free survival in patients with metastatic hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer treated with first-line ribociclib and endocrine therapy: real-world data from the RIBANNA study (2025) Decker T, Brucker C, Engel A, Fasching P, Göhler T, Jackisch C, Janssen J, et al. Journal article Real-world risk of recurrence and treatment outcomes with adjuvant endocrine therapy in patients with stage II-III HR+/HER2- early breast cancer (2025) O'Shaughnessy J, Tolaney SM, Yardley DA, Hart L, Razavi P, Fasching P, Janni W, et al. Journal article